Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy by Chun Li, Ute I. Schwarz, Marylyn D. Ritchie, Dan M. Roden, C. Michael Stein, and Daniel Kurnik Blood Volume 113(17):3925-3930 April 23, 2009 ©2009 by American Society of Hematology

Comparison of goodness of fit (R2) among 4 models for each of the 3 outcome variables. Comparison of goodness of fit (R2) among 4 models for each of the 3 outcome variables. (A) Time to INR ≥ the lower limit of therapeutic range. (B) Time to INR > 4. (C) Early stable warfarin dose. In each panel, the first bar (□) represents the baseline model (including age, ethnicity, sex, amiodarone use, target INR, and cumulative warfarin dose); second bar (), the baseline model + VKORC1 / CYP2C9 genotypes; the third bar (), the baseline model + early INR values; fourth bar (■), the full model. The difference between the last 2 bars (■ and ) in each panel represents the contribution of genotypes after adjustment for baseline covariates and INRearly. Chun Li et al. Blood 2009;113:3925-3930 ©2009 by American Society of Hematology